UBS Group Cuts MetLife (NYSE:MET) Price Target to $82.00

MetLife (NYSE:METFree Report) had its price target decreased by UBS Group from $87.00 to $82.00 in a research note issued to investors on Monday, Benzinga reports. UBS Group currently has a buy rating on the financial services provider’s stock.

Other research analysts have also issued research reports about the company. The Goldman Sachs Group raised MetLife from a neutral rating to a buy rating and raised their price objective for the company from $70.00 to $80.00 in a research report on Monday, January 8th. Morgan Stanley lifted their target price on MetLife from $79.00 to $80.00 and gave the stock an overweight rating in a report on Thursday, November 2nd. Keefe, Bruyette & Woods reduced their target price on MetLife from $79.00 to $77.00 and set an outperform rating for the company in a report on Thursday, December 7th. Finally, Barclays restated an overweight rating and issued a $71.00 price target on shares of MetLife in a research note on Friday, November 17th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of Moderate Buy and an average price target of $77.23.

View Our Latest Analysis on MET

MetLife Trading Up 1.6 %

MET opened at $67.00 on Monday. MetLife has a 52 week low of $48.95 and a 52 week high of $73.12. The company has a quick ratio of 0.13, a current ratio of 0.16 and a debt-to-equity ratio of 0.53. The stock has a market cap of $49.59 billion, a PE ratio of 36.61, a PEG ratio of 0.54 and a beta of 1.04. The business has a 50 day moving average of $67.00 and a 200-day moving average of $64.00.

MetLife Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 14th. Stockholders of record on Tuesday, February 6th will be issued a $0.52 dividend. The ex-dividend date is Monday, February 5th. This represents a $2.08 annualized dividend and a dividend yield of 3.10%. MetLife’s dividend payout ratio (DPR) is 113.66%.

Institutional Investors Weigh In On MetLife

Several large investors have recently made changes to their positions in MET. Norges Bank bought a new stake in MetLife during the fourth quarter worth approximately $444,205,000. Pzena Investment Management LLC increased its stake in MetLife by 118.1% during the third quarter. Pzena Investment Management LLC now owns 10,108,992 shares of the financial services provider’s stock worth $635,957,000 after acquiring an additional 5,474,449 shares during the last quarter. Franklin Resources Inc. increased its stake in MetLife by 499.6% during the second quarter. Franklin Resources Inc. now owns 4,073,174 shares of the financial services provider’s stock worth $230,257,000 after acquiring an additional 3,393,875 shares during the last quarter. Moneta Group Investment Advisors LLC bought a new stake in MetLife during the fourth quarter worth approximately $234,761,000. Finally, DekaBank Deutsche Girozentrale increased its stake in MetLife by 806.2% during the third quarter. DekaBank Deutsche Girozentrale now owns 1,607,195 shares of the financial services provider’s stock worth $100,152,000 after acquiring an additional 1,429,840 shares during the last quarter. 88.14% of the stock is owned by institutional investors.

About MetLife

(Get Free Report)

MetLife, Inc, a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements.

See Also

Analyst Recommendations for MetLife (NYSE:MET)

Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.